JP2023520188A - 感染を予防又は治療するための技術 - Google Patents

感染を予防又は治療するための技術 Download PDF

Info

Publication number
JP2023520188A
JP2023520188A JP2022557130A JP2022557130A JP2023520188A JP 2023520188 A JP2023520188 A JP 2023520188A JP 2022557130 A JP2022557130 A JP 2022557130A JP 2022557130 A JP2022557130 A JP 2022557130A JP 2023520188 A JP2023520188 A JP 2023520188A
Authority
JP
Japan
Prior art keywords
xaa
independently
amino acid
salt
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520188A5 (https=
Inventor
セルゲイ バイデン，アレキサンダー
ベルバソヴァ，タチアナ
エマーソン フィッシャー，ローレンス
カズミエルスキー，ヴィスラフ
ラステリ，ルカ
ケイ． ソーヤー，トミ
アダム スピーゲル，デヴィッド
チャールズ ウィディソン，ウェイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2023520188A publication Critical patent/JP2023520188A/ja
Publication of JP2023520188A5 publication Critical patent/JP2023520188A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022557130A 2020-03-25 2021-03-25 感染を予防又は治療するための技術 Pending JP2023520188A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062994779P 2020-03-25 2020-03-25
US62/994,779 2020-03-25
US202063001455P 2020-03-29 2020-03-29
US63/001,455 2020-03-29
US202063055860P 2020-07-23 2020-07-23
US63/055,860 2020-07-23
PCT/US2021/024186 WO2021195401A1 (en) 2020-03-25 2021-03-25 Technologies for preventing or treating infections

Publications (2)

Publication Number Publication Date
JP2023520188A true JP2023520188A (ja) 2023-05-16
JP2023520188A5 JP2023520188A5 (https=) 2024-04-03

Family

ID=77890439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557130A Pending JP2023520188A (ja) 2020-03-25 2021-03-25 感染を予防又は治療するための技術

Country Status (12)

Country Link
US (1) US20230330240A1 (https=)
EP (1) EP4125893A4 (https=)
JP (1) JP2023520188A (https=)
KR (1) KR20220158762A (https=)
CN (1) CN115697415A (https=)
AU (1) AU2021244228A1 (https=)
BR (1) BR112022018945A2 (https=)
CA (1) CA3176256A1 (https=)
IL (1) IL296725A (https=)
MX (1) MX2022011692A (https=)
PH (1) PH12022552499A1 (https=)
WO (1) WO2021195401A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
CN116440285A (zh) * 2023-04-19 2023-07-18 山西锦波生物医药股份有限公司 冠状病毒多肽类融合抑制剂的长效化的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069986A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. Universal abt compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG, G. ET AL.: "The first-in-classpeptide binder to the SARS-CoV-2 spike protein", BIORXIV, JPN6025010422, 20 March 2020 (2020-03-20), pages 1 - 15, ISSN: 0005552577 *

Also Published As

Publication number Publication date
US20230330240A1 (en) 2023-10-19
MX2022011692A (es) 2023-02-09
BR112022018945A2 (pt) 2022-12-13
CA3176256A1 (en) 2021-09-30
EP4125893A4 (en) 2024-10-16
EP4125893A1 (en) 2023-02-08
KR20220158762A (ko) 2022-12-01
PH12022552499A1 (en) 2024-03-25
IL296725A (en) 2022-11-01
AU2021244228A1 (en) 2022-11-17
WO2021195401A1 (en) 2021-09-30
CN115697415A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
US20230128688A1 (en) Directed conjugation technologies
EP4362933A1 (en) Complement inhibition
US20200360381A1 (en) Compounds for treating dengue virus infection and other viral infections
JP2019510810A (ja) インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）阻害剤
JP2013528229A (ja) 多価糖ペプチド構築物およびその使用
JP2023520188A (ja) 感染を予防又は治療するための技術
KR20230057350A (ko) 스테이플화된 펩티드 및 이의 방법
JP7793506B2 (ja) Ｃｄ３８に結合する薬剤およびその使用
WO2023121753A1 (en) Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent
US20250108124A1 (en) Antibody drug conjugates using mates technology for delivering cytotoxic agents
US20210230101A1 (en) Compounds for treating dengue virus infections and other infections
US20240335555A1 (en) Technologies for preventing or treating infections
JP2025541247A (ja) ステープルペプチドおよびその方法
JP2025541246A (ja) ステープルペプチドおよびその方法
KR20230148830A (ko) 표적화된 이기능성 분해제 및 이의 사용 방법
US20240391956A1 (en) Stapled peptides and methods thereof
HK40129655A (zh) 订书钉化肽及其方法
KR20260035134A (ko) 스테이플화 펩티드 및 이의 방법
HK40128981A (zh) 订书钉化肽及其方法

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221215

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909